Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$11.52 USD

11.52
586,118

+0.31 (2.77%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 244)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

by Zacks Equity Research

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

Kinjel Shah headshot

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

by Kinjel Shah

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Zacks Equity Research

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

by Zacks Equity Research

Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.

Zacks Equity Research

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Theravance's Q4 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Zacks Equity Research

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

by Zacks Equity Research

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

by Kinjel Shah

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 9.74% and 13.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 3.70% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?

by Zacks Equity Research

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -44.44% and 9.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Momentum Stocks to Buy for July 15th

by Zacks Equity Research

TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.

Zacks Equity Research

New Strong Buy Stocks for July 15th

by Zacks Equity Research

TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.